Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
Maseda E, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofiño A, Roberts JA, Aguilar L, Luque S, Sevillano D, Gimenez MJ, Gilsanz F. Maseda E, et al. Among authors: sevillano d. J Antimicrob Chemother. 2014 Jun;69(6):1624-32. doi: 10.1093/jac/dku013. Epub 2014 Feb 5. J Antimicrob Chemother. 2014. PMID: 24505092
The use of a thin guide-wire for urethral definition in prostate SBRT treatments with Cyberknife.
Sevillano D, Hervás A, García-Fuentes JD, Vallejo C, López F, Colmenares R, Capuz AB, Morís R, Cámara M, Galiano P, Williamson S, Chillida R, Béjar MJ, Prieto D, García-Vicente F. Sevillano D, et al. J Appl Clin Med Phys. 2023 Aug;24(8):e14006. doi: 10.1002/acm2.14006. Epub 2023 Apr 25. J Appl Clin Med Phys. 2023. PMID: 37097754 Free PMC article.
Evaluation of a high resolution diode array for CyberKnife quality assurance.
García-Fuentes JD, Sevillano D, Colmenares R, Capuz AB, Morís R, Cámara M, Galiano P, Williamson S, Béjar MJ, Prieto D, García-Vicente F. García-Fuentes JD, et al. Among authors: sevillano d. J Appl Clin Med Phys. 2023 Sep;24(9):e14053. doi: 10.1002/acm2.14053. Epub 2023 May 29. J Appl Clin Med Phys. 2023. PMID: 37247259 Free PMC article.
Do face masks increase the rate of the Staphylococcus aureus nasal carriers?
Urquía-Cutillas S, Gómez-Lus ML, Sevillano D, González N, Alou L. Urquía-Cutillas S, et al. Among authors: sevillano d. Rev Esp Quimioter. 2023 Oct;36(5):549-551. doi: 10.37201/req/082.2023. Epub 2023 Sep 7. Rev Esp Quimioter. 2023. PMID: 37675477 Free PMC article. No abstract available.
3Y-TZP/Ta Biocermet as a Dental Material: An Analysis of the In Vitro Adherence of Streptococcus Oralis Biofilm and an In Vivo Pilot Study in Dogs.
Smirnov A, Yanushevich O, Krikheli N, Solis Pinargote NW, Peretyagin P, Grigoriev S, Alou L, Sevillano D, López-Piriz R, Guitian F, Bartolomé JF. Smirnov A, et al. Among authors: sevillano d. Antibiotics (Basel). 2024 Feb 9;13(2):175. doi: 10.3390/antibiotics13020175. Antibiotics (Basel). 2024. PMID: 38391561 Free PMC article.
In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J. Amores R, et al. Among authors: sevillano d. Int J Antimicrob Agents. 2004 Jul;24(1):79-82. doi: 10.1016/j.ijantimicag.2004.01.016. Int J Antimicrob Agents. 2004. PMID: 15225866
Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J. Sevillano D, et al. J Antimicrob Chemother. 2004 Dec;54(6):1148-51. doi: 10.1093/jac/dkh463. Epub 2004 Oct 15. J Antimicrob Chemother. 2004. PMID: 15489246
Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J. Alou L, et al. Among authors: sevillano d. J Antimicrob Chemother. 2005 May;55(5):742-7. doi: 10.1093/jac/dki071. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761068 Clinical Trial.
99 results